

UNITED STATES DISTRICT COURT  
DISTRICT OF DELAWARE

UNITED STATES OF AMERICA, )  
 )  
 Plaintiff, )  
 )  
 v. )  
 )  
 ROOS FOODS, INC., )  
 a corporation, )  
 )  
 and )  
 )  
 ANA A. ROOS and VIRGINIA )  
 MEJIA, individuals, )  
 )  
 Defendants. )  
 \_\_\_\_\_ )

Civil No. \_\_\_\_\_

CONSENT DECREE OF  
PERMANENT INJUNCTION

MISC. CASE # 16-29  
U.S. DISTRICT COURT  
DISTRICT OF DELAWARE

FILED  
CLERK U.S. DISTRICT COURT  
DISTRICT OF DELAWARE  
2016 JAN 22 AM 9:30  
*Bl*  
*fee waived*

Plaintiff, United States of America, by its undersigned attorneys, having filed a Complaint for Permanent Injunction against Roos Foods, Inc. ("Roos Foods"), a corporation, and Ana A. Roos and Virginia Mejia, individuals (collectively "Defendants"), alleging the following:

A. Defendants violate the Act, 21 U.S.C. § 331(a), by introducing or delivering for introduction, or causing to be introduced or delivered for introduction, into interstate commerce articles of food, within the meaning of 21 U.S.C. § 321(f), that are adulterated within the meaning of 21 U.S.C. § 342(a)(4);

B. Defendants violate the Act, 21 U.S.C. § 331(k), by adulterating, or causing the adulteration of, articles of food within the meaning of 21 U.S.C. § 342(a)(4) while such articles are held for sale after shipment of one or more ingredients in interstate commerce; and

Defendants, without admitting or denying the allegations of the Complaint, having appeared and consented to entry of this Consent Decree of Permanent Injunction (“Decree”) without contest and before any testimony has been taken, and the United States of America having consented to this Decree:

IT IS HEREBY ORDERED, ADJUDGED, AND DECREED that:

1. This Court has jurisdiction over the subject matter and over all parties to this action.
2. The Complaint for Permanent Injunction states a cause of action against Defendants under the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 301 et seq.
3. For the purposes of this Decree,  
“Roos facility(ies)” include(s):
  - (1) 251 Roos Lane, Kenton, Delaware;
  - (2) 193 Cooper Street, Kenton, Delaware; and/or
  - (3) any other locations at or from which Defendants, now or in the future, receive, prepare, process, pack, hold, or distribute any articles of food.
4. Defendants represent to the Court that, at the time of entry of this Decree, they are not engaged in receiving, preparing, processing, packing, holding, or distributing any type of food at or from any location.
5. If Defendants later intend to resume receiving, preparing, processing, packing, holding, or distributing food at or from any Roos facility(ies), they must first notify the United States Food and Drug Administration (“FDA”) in writing at least ninety (90) calendar days in advance of resuming operations and comply with paragraphs 6(A) - (K) of this Decree. This notice shall identify the type(s) of food Defendants intend to receive, prepare, process, pack, hold, or distribute at or from the Roos facility(ies). Defendants shall not resume operations until

FDA has inspected the Roos facility(ies) and operations pursuant to paragraph 6(I), Defendants have paid the costs of such inspection(s) pursuant to paragraph 14, and Defendants have received written notice from FDA, as required by paragraph 6(J), and then shall resume operations only to the extent authorized in FDA's written notice.

6. Defendants and each and all of their officers, agents, employees, representatives, successors, assigns, heirs, attorneys, and any and all persons in active concert or participation with any of them (including individuals, directors, corporations, subsidiaries, affiliates, and partnerships) are hereby permanently restrained and enjoined, under the provisions of 21 U.S.C. § 332(a) and the equitable authority of this Court, from directly or indirectly receiving, preparing, processing, packing, holding, and/or distributing articles of food, at or from any Roos facility(ies), unless and until:

A. Defendants retain, at their expense, an independent laboratory (the "laboratory") having no personal or financial ties (other than the retention agreement) to Defendants or their families, which is qualified to collect product and environmental samples from within the Roos facility(ies) and analyze those samples for the presence of *Listeria*, including *Listeria monocytogenes* ("*L. mono*"), in a method that is acceptable to FDA. Defendants shall notify FDA in writing immediately upon retaining such laboratory and shall provide FDA a copy of the service contract. Such service contract shall contain certain provisions, acceptable to FDA, for regular environmental and finished product sample collection and analyses, including how and where to sample, the number and frequency of samples to be collected, and the methods of analyses, in accordance with the *Listeria* Monitoring Program discussed in paragraph 6(C) below;

B. Defendants retain, at their expense, an independent expert(s) (the

“sanitation expert”) having no personal or financial ties (other than the retention agreement) to Defendants or their families, and who, by reason of background, education, training, and experience, is qualified to inspect the Roos facility(ies) and to determine whether the methods, facility(ies), and controls are operated and administered in conformity with the Act and 21 C.F.R. Part 110. Defendants shall notify FDA in writing of the name(s) and qualifications of the sanitation expert(s) as soon as they retain such expert(s);

C. Defendants’ sanitation expert, in consultation with the laboratory, after reviewing all FDA and Delaware Division of Public Health (“DDPH”) observations from July 2010 to present for the Roos Foods facility located at 251 Roos Lane, Kenton, Delaware, develops a written *Listeria* Monitoring Program, which shall include, at a minimum, the following:

(1) An effective written sanitation control program that establishes adequate methods, facility(ies), and controls for receiving, preparing, processing, packing, holding, and distributing articles of food to minimize the risk of introduction of pathogenic *Listeria*, other pathogenic microorganisms, any other poisonous or deleterious substance, or filth into Defendants’ food, and to ensure that Defendants’ foods are not adulterated within the meaning of 21 U.S.C. § 342(a). Such methods, facility(ies), and controls shall include, but shall not be limited to, thoroughly cleaning, sanitizing, renovating, and rendering the facility(ies) and all equipment therein suitable for use in receiving, preparing, processing, packing, holding, and distributing articles of food to prevent such articles from becoming adulterated, and instituting standard sanitation operating procedures (“SSOPs”) to ensure that the facility(ies) and equipment therein are continuously maintained in a sanitary condition;

(2) A written employee training program (in English and Spanish) that includes, at a minimum, instruction on sanitary food handling techniques and documentation that each employee has received such training. Defendants' sanitation expert shall ensure that each employee fully understands the substance of the employee training program;

(3) An effective program of environmental monitoring and testing of the Roos facility(ies) to ensure that microorganisms such as *Listeria*, any other poisonous or deleterious substance, and filth are not present within the facility(ies). Environmental monitoring shall include, but not be limited to, collecting swab samples from food-contact surfaces, equipment, and other environmental sites throughout the Roos facility(ies) (where the raw ingredients, in-process, and finished articles of foods are received, prepared, processed, packed, held, and/or distributed, and common areas that could be reservoirs for cross-contamination), and analyzing collected samples, in a manner acceptable to FDA. Defendants shall ensure that the results of all analyses conducted pursuant to this paragraph are sent to FDA within two (2) business days after receipt by Defendants; and

(4) A written plan for remedial action should pathogenic *Listeria*, any other pathogenic microorganisms, any other poisonous or deleterious substance, and/or filth be detected;

D. Defendants assign continuing responsibility for the operation of the *Listeria* Monitoring Program to a person or persons who, by reason of background, experience, or education, is competent to maintain the facility(ies) in a sanitary condition, coordinate with the laboratory, and implement any necessary remedial action(s), and provide such person with the authority to achieve the necessary corrections;

E. FDA approves, in writing, the *Listeria* Monitoring Program discussed in

paragraph 6(C) prior to implementation;

F. The sanitation expert conducts a comprehensive inspection of the Roos facility(ies) and the methods and controls used to receive, prepare, process, pack, hold, and distribute foods to determine whether Defendants have effectively implemented all necessary corrections and are operating in compliance with this Decree, the Act, and 21 C.F.R. Part 110. The expert shall submit all findings to Defendants and FDA concurrently, within ten (10) business days after completion of the inspection;

G. Defendants report to FDA in writing the actions they have taken to bring the operations at the Roos facility(ies) into compliance with the Act and all applicable regulations, including:

(1) Documentation that Defendants have cleaned and sanitized the Roos facility(ies) and equipment therein and made improvements, thereby rendering the Roos facility(ies) and equipment therein suitable for receiving, processing, preparing, packing, holding, and distributing articles of food, and documentation that Defendants have conducted environmental testing in a manner acceptable to FDA and received laboratory results showing that *Listeria* is no longer present in the Roos facility(ies) or on the equipment therein; and

(2) Specific measures that they have taken to address each of the violations documented by FDA and DDPH for the Roos Foods facility located at 251 Roos Lane, Kenton, Delaware, since July 2010.

H. Within twenty (20) business days upon entry of this Decree, Defendants destroy, under FDA's supervision, and according to a destruction plan submitted in writing by Defendants and approved in writing by FDA prior to implementation, all in-process and finished articles of food currently in their custody, control, or possession at the Roos facility(ies);

I. FDA, as it deems necessary to evaluate Defendants' compliance with the terms of this Decree, the Act, and all applicable regulations, conducts inspections of the Roos facility(ies), including the buildings, sanitation-related systems, equipment, utensils, all articles of food, and relevant records contained therein. Defendants shall ensure that all relevant records are readily accessible at all times;

J. FDA notifies Defendants in writing that Defendants appear to be in compliance with the requirements set forth in paragraph 6(A) through (H) of this Decree, the Act, and 21 C.F.R. Part 110; and

K. Defendants have paid all costs of inspection, analyses, review, investigations, examination, and supervision for FDA's oversight with respect to paragraph 6(A) through (J), at the rates set forth in paragraph 14 below.

7. Defendants and each and all of their officers, agents employees, representatives, successors, assigns, heirs, attorneys, and any and all persons in active concert or participation with any of them (including individuals, directors, corporations, subsidiaries, affiliates, and partnerships) who receive actual notice of this Decree pursuant to paragraph 23 below, are permanently restrained and enjoined under the provisions of 21 U.S.C. § 332(a) from directly or indirectly doing or causing any act that:

A. violates the Act, 21 U.S.C. § 331(a), by introducing or delivering for introduction, or causing to be introduced or delivered for introduction, into interstate commerce articles of food that are adulterated within the meaning of 21 U.S.C. § 342(a)(4);

B. violates the Act, 21 U.S.C. § 331(k), by causing articles of food to be adulterated within the meaning of 21 U.S.C. § 342(a)(4) while such articles are held for sale after shipment of one or more ingredients in interstate commerce; or

C. results in the failure to implement and continuously maintain the applicable requirements of this Decree.

8. Notwithstanding paragraph 7, Defendant Virginia Mejia may participate in the marketing of food products for any corporation, partnership, firm, company, business, entity, and/or persons, other than the remaining Defendants.

A. Defendant Virginia Mejia shall notify FDA in writing at least ten (10) business days prior to becoming employed by, or otherwise engaged with, any corporation, partnership, firm, company, business, entity, and/or persons that is/are engaged in receiving, preparing, processing, packing, holding, or distributing any type of food ("Mejia employer(s)"), and such notification shall include the name(s) and address(es) of the Mejia employer(s).

B. Defendant Mejia also shall provide to FDA an affidavit with a detailed description of her employment duties at and/or for the Mejia employer(s) within ten (10) business days of beginning her employment. If Defendant Virginia Mejia's employment duties significantly change during the course of her employment at and/or for the Mejia employer(s), Defendant Virginia Mejia shall provide to FDA an affidavit detailing her new employment duties within ten (10) business days of assuming the new employment duties. In no circumstances shall Defendant Virginia Mejia's employment duties at a Mejia employer extend beyond marketing of food products.

9. Immediately upon resuming operations at any Roos facility(ies) after completing the requirements of paragraph 6 and receiving written notice from FDA pursuant to paragraph 6(J), Defendants shall, in consultation with the laboratory and the sanitation expert, continuously implement the following steps to prevent adulteration of food received, prepared, processed, packed, held in, and/or distributed from, Defendants' facility(ies):



A. Effectively implement, on an ongoing basis, the *Listeria* Monitoring Program developed pursuant to paragraph 6(C).

B. Conduct environmental monitoring and testing as set forth in paragraph 6(C)(3) to ensure that the SSOPs continue to eliminate the *Listeria* hazard and that the SSOPs are consistently followed. Environmental testing shall be performed by the laboratory in accordance with timetables and methods that Defendants submit in writing to FDA for prior written approval by FDA. Defendants shall ensure that the results of all testing conducted pursuant to this paragraph are forwarded to FDA within two (2) business days after receipt by Defendants.

Defendants' environmental testing must include, at a minimum, all of the following:

(1) if a food- or non-food-contact surface tests positive for *Listeria* during routine testing, intensified sampling must be initiated immediately, in conjunction with intensified sanitation measures. Intensified sampling requires that three (3) samples per day must be collected and analyzed until a total of nine (9) consecutive samples (three (3) days of intensified sampling) have tested negative for *Listeria* from the site where the *Listeria* was identified. After nine (9) consecutive samples have tested negative for *Listeria*, that site may be subject to routine sampling; and

(2) all food in contact with a Zone 2 and Zone 3 (non-food contact) site that tests positive for *Listeria* must be quarantined and tested for pathogenic *Listeria*. Food that tests negative for pathogenic *Listeria* may be released from quarantine; food testing positive for pathogenic *Listeria*, as well as all food manufactured since the positive laboratory sample(s) were collected, must be destroyed pursuant to a written destruction plan approved in writing by FDA. Further, all food in contact with a Zone 1 (direct food contact) site that tests positive for *Listeria*, as well as all food manufactured since the positive laboratory sample(s) were collected,

must be destroyed pursuant to a written destruction plan approved by FDA. Defendants shall bear the costs of such destruction and the costs of FDA's supervision of such destruction, at the rates specified in paragraph 14; and

C. Conduct finished product testing in the following manner:

(1) Defendants shall test for pathogenic *Listeria* in all lots of each food product for at least five (5) consecutive production days using a testing method approved in advance by FDA;

(2) After the completion of testing under paragraph 9(C)(1), Defendants shall test at least one lot of each food product per day for the next twenty (20) production days;

(3) After the completion of testing under paragraph 9(C)(2), Defendants shall test at least one lot of each food product per every five (5) production days for the next three (3) months; and

(4) After the completion of testing under paragraph 9(C)(3), Defendants shall test at least one lot of each food product per month thereafter.

(5) If any laboratory test completed pursuant to paragraphs 9(C)(1)-(4) shows the presence of pathogens, including *L. mono*, in any article of food, then Defendants must immediately cease production and notify FDA that production has ceased. Defendants shall also destroy, at Defendants' expense, under FDA's supervision, and pursuant to a written destruction plan approved in writing by FDA prior to implementation, all positive food samples, as well as all food manufactured since the positive samples were collected. Defendants may resume production only when they have determined and corrected the cause of the contamination and only after FDA notifies Defendants in writing that Defendants appear to be in compliance with the requirements of this Decree, the Act, and 21 C.F.R. Part 110. After correcting the cause of

the contamination, Defendants shall reinstate the complete sequence of testing under this paragraph anew. Defendants shall ensure that the results of all testing conducted pursuant to this paragraph are forwarded to FDA within two (2) business days after receipt by Defendants.

10. If Defendants terminate or alter in any way their service contract with the laboratory retained for the Roos facility(ies) pursuant to paragraph 6(A), Defendants shall notify FDA within five (5) business days after such termination or alteration. If Defendants terminate their service contract, Defendants shall provide a copy of the service contract with the new laboratory to FDA within five (5) business days after such service contract is executed.

11. FDA shall be permitted, without prior notice and as when FDA deems necessary, to make inspections of the Roos facility(ies), and without prior notice, to take any other measures necessary to monitor and ensure continuing compliance with the terms of this Decree, the Act, and its implementing regulations. During the inspections of the Roos facility(ies), FDA shall be permitted to have immediate access to buildings, equipment, raw ingredients, in-process and finished articles of food, containers, and packaging material therein; to take photographs and make video recordings; to take samples of Defendants' raw ingredients, in-process, and finished articles of food, containers, and packaging material; and to examine and copy all records related to receiving, preparing, processing, packing, holding, and distributing any and all articles of food. The inspections shall be permitted upon presentation of a copy of this Decree and appropriate credentials. The inspection authority granted by this Decree is apart from, and in addition to, the authority to make inspections under the Act, 21 U.S.C. § 374.

12. Defendants shall notify FDA in writing at least fifteen (15) business days before any change in ownership, name, or character of their business, including reorganization, relocation, dissolution, assignment, or lease or sale of the business or any assets of the business, such as

buildings, equipment, or inventory, that may affect compliance with the obligations arising from this Decree. Defendants shall provide any prospective successor or assign with a copy of this Decree at least ten (10) business days before the assignment or change in business, and shall provide FDA with an affidavit of compliance with this paragraph within ten (10) business days after providing a copy of this Decree to a prospective successor or assign.

13. At least ten (10) business days prior to Defendants selling, leasing, transferring, relocating, and/or moving in any fashion food manufacturing equipment from the Roos facility(ies) to any location where food is received, prepared, processed, packed, held, or distributed Defendants shall submit written documentation to FDA certifying that the equipment has been cleaned and sanitized in a manner acceptable to FDA.

14. Defendants shall reimburse FDA for the costs of all FDA inspections of the Roos facility(ies), investigations, supervision, analyses, examinations, and reviews that FDA deems necessary to evaluate Defendants' compliance with this Decree, at the prevailing rates in effect at the time the costs are incurred. As of the date that this Decree is signed by the parties, these rates are: \$88.45 per hour and fraction thereof per representative for inspection work; \$106.03 per hour or fraction thereof per representative for analytical or review work; \$0.56 per mile for travel by automobile; government rate or the equivalent for travel by air or other means; and the published government per diem rate or the equivalent for the areas in which the inspections are performed per representative and per day for subsistence expenses, where necessary. In the event that the standard rates applicable to FDA supervision of court-ordered compliance are modified, these rates shall be increased or decreased without further order of the Court.

15. If, at any time after entry of this Decree, FDA determines, based on the results of an inspection, sample analyses, or other information, that one or more Defendants have failed to

comply with any applicable provision of this Decree, have violated the Act or its implementing regulations, or that additional corrective actions are necessary to achieve compliance with this Decree, the Act, or its implementing regulations, FDA may, as and when it deems necessary, notify such Defendant(s) in writing and order such Defendant(s) to take appropriate action, including, but not limited to, ordering such Defendant(s) to immediately take one or more of the following actions:

- A. Cease receiving, preparing, processing, packing, holding, and/or distributing any articles of food at or from the Roos facility(ies);
- B. Recall all articles of food that have been distributed or are under the custody and control of such Defendant's(s') agents, distributors, customers, or consumers;
- C. Submit samples of articles of food to a qualified laboratory to determine whether they are contaminated with chemicals, toxins, microorganisms, or filth; and/or
- D. Take any other corrective actions as FDA deems necessary to bring such Defendant(s) into compliance with this Decree, the Act, and its implementing regulations.

The provisions of this paragraph shall be separate and apart from, and in addition to, all other remedies available to FDA. Defendant(s) who receive notification under this paragraph shall pay all costs of recalls and other corrective actions, including the costs of FDA's supervision, inspections, investigations, analyses, examinations, review, travel, and subsistence expenses to implement and monitor recalls and other corrective actions, at the rates specified in paragraph 14 of this Decree.

16. Any cessation of operations as described in paragraph 15(A) shall be implemented immediately upon notice from FDA and shall continue until such Defendant(s) receive written notification from FDA that such Defendant(s) appear(s) to be in compliance with the Decree, the

Act, and its implementing regulations. After a cessation of operations, and while determining whether such Defendant(s) is/are in compliance with the Decree, the Act, and its implementing regulations, FDA may require such Defendant(s) to re-institute or re-implement any of the requirements of this Decree.

17. If Defendants fail to comply with the provisions of the Act, its implementing regulations, and/or this Decree, then Defendants shall pay to the United States of America liquidated damages in the sum of two thousand dollars (\$2,000.00) for each day that Defendants fail to comply with this Decree; an additional sum of one thousand dollars (\$1,000.00) in liquidated damages per day for each violation of the Act, its implementing regulations, and/or this Decree; and an additional sum equal to twice the retail value of each shipment of adulterated food. Defendants understand and agree that the liquidated damages specified in this paragraph are not punitive in nature and their imposition does not in any way limit the ability of the United States to seek, and the Court to impose, additional criminal or civil penalties based on conduct that may also be the basis for payment of the liquidated damages.

18. If any Defendant violates applicable provisions of this Decree and is found in contempt thereof, such Defendant(s) shall, in addition to other remedies, reimburse Plaintiff for its attorneys' fees, travel expenses incurred by attorneys and witnesses, expert witness fees, administrative and court costs, investigation and analytical expenses incurred in bringing the contempt action, and any other costs or fees related to the contempt proceedings.

19. All decisions specified in this Decree shall be vested in the discretion of FDA. FDA's decisions shall be final and, to the extent that these decisions are subject to review, shall be reviewed by the Court under the arbitrary and capricious standard set forth in 5 U.S.C. § 706(2)(A). Review by the Court of any FDA decision rendered pursuant to this Decree shall

be based exclusively on the written record before FDA at the time the decision was made. No discovery shall be taken by either party.

20. Within ten (10) business days after entry of this Decree, Defendants shall provide a copy of this Decree to each and all of their officers, agents, employees, representatives, successors, assigns, heirs, attorneys, and any and all persons in active concert or participation with any of them (including individuals, directors, corporations, subsidiaries, affiliates, and partnerships). Defendants shall provide to FDA within twenty (20) business days after the date of entry of this Decree, an affidavit of compliance with this paragraph stating the fact and manner of compliance and identifying the names and positions of all persons so notified.

21. Defendants shall prominently post a copy of this Decree (in English and Spanish) in an employee common area at the Roos facility(ies) within ten (10) business days after entry of this Decree and shall ensure that the Decree remains posted for a period of at least six (6) months.

22. Defendants shall, within ten (10) business days after entry of this Decree, hold a general meeting or series of smaller meetings for employees of the Roos facility(ies), at which they shall describe the terms and obligations of this Decree.

23. In the event that any Defendant(s) become(s) associated with any additional officers, agents, employees, representatives, successors, assigns, heirs, attorneys, or any additional persons in active concert or participation with any of them (including individuals, directors, corporations, subsidiaries, affiliates, and partnerships) at any time after entry of this Decree, such Defendant(s) shall immediately provide a copy of this Decree, by personal service or certified mail (restricted delivery, return receipt requested), to such persons. Within ten (10) business days after each instance that any Defendant becomes associated with any such additional

persons, such Defendant(s) shall provide to FDA an affidavit stating the fact and manner of such Defendant's(s') compliance with this paragraph, identifying the names, addresses, and positions of all person who received a copy of this Decree pursuant to this paragraph, and attaching a copy of the executed certified mail return receipts. Within ten (10) business days after receiving a request from FDA for any information or documentation that FDA deems necessary to evaluate Defendants' compliance with this paragraph, Defendants shall provide such information or documentation to FDA.

24. This Decree resolves only the claims in this statutory injunction action brought under 21 U.S.C. § 332(a) as set forth in the Complaint. Defendants specifically state and agree that entry of this Decree does not preclude any other civil, criminal, or administrative claims that the government may have or may bring in the future against any of the Defendants herein in connection with, or relating to, any of the Defendants' activities involving FDA-regulated products, including the conduct alleged in the Complaint filed with this Decree.

25. Defendants shall address all communications with FDA required under this Decree to the Director, Philadelphia District Office, United States Food and Drug Administration, U.S. Customhouse, 2nd & Chestnut Sts., Room 900, Philadelphia, Pennsylvania 19106, and shall reference this civil action by case name and civil action number in such communications.

26. This Court shall retain jurisdiction of this action and the parties hereto for the purpose of enforcing or modifying this Decree and for the purpose of granting such additional relief as may be necessary or appropriate.




SO ORDERED:


Dated this \_\_\_\_\_ day of \_\_\_\_\_, 2014.


UNITED STATES DISTRICT JUDGE


We hereby consent to the entry of the foregoing Decree:

For Defendant:

  
ANA A. ROOS  
Individually and on behalf of Roos  
Foods Inc.

  
VIRGINIA MEJIA  
Individually

  
EDMUND DANIEL LYONS  
Attorney for Defendants Ana A. Roos  
and Virginia Mejia

  
K/20 Jan 9  
1/15/16

For Plaintiff:

JOYCE BRANDA  
Acting Assistant Attorney General

JONATHAN F. OLIN  
Deputy Assistant Attorney General

CHARLES M. OBERLY, III  
United States Attorney

MICHAEL S. BLUME  
Director  
Consumer Protection Branch

Patricia Hannigan  
Assistant United States Attorney  
1007 N. Orange Street  
P.O. Box 2046  
Wilmington, DE 19899

Mary M. Englehart  
Trial Attorney  
U.S. Department of Justice  
Consumer Protection Branch  
6<sup>th</sup> Floor South  
450 Fifth Street, N.W.  
Washington, DC 20001

Of Counsel:

WILLIAM B. SCHULTZ


SO ORDERED:


Dated this \_\_\_\_\_ day of \_\_\_\_\_, 2014.


UNITED STATES DISTRICT JUDGE

We hereby consent to the entry of the foregoing Decree:

For Defendant:

  
ANA A. ROOS  
Individually and on behalf of Roos  
Foods Inc.

  
VIRGINIA MEJIA  
Individually

  
EDMUND DANIEL LYONS  
Attorney for Defendants Ana A. Roos  
and Virginia Mejia


For Plaintiff:


JOYCE BRANDA  
Acting Assistant Attorney General

JONATHAN F. OLIN  
Deputy Assistant Attorney General

CHARLES M. OBERLY, III  
United States Attorney

MICHAEL S. BLUMB  
Director  
Consumer Protection Branch

  
Patricia Hannigan Delaware Bar ID: 2145  
Assistant United States Attorney  
1007 N. Orange Street  
P.O. Box 2046  
Wilmington, DE 19899

  
Mary M. Englishhart  
Trial Attorney  
U.S. Department of Justice  
Consumer Protection Branch  
6<sup>th</sup> Floor South  
450 Fifth Street, N.W.  
Washington, DC 20001

Of Counsel:

WILLIAM B. SCHULTZ

General Counsel

ELIZABETH H. DICKINSON  
Chief Counsel  
Food and Drug Division

ANNAMARIE KEMPIC  
Deputy Chief Counsel for Litigation

SHANNON M. SINGLETON  
Assistant Chief Counsel for Enforcement  
United States Department of Health and  
Human Services  
Office of the General Counsel  
Food and Drug Administration  
10903 New Hampshire Avenue  
Silver Spring, MD 20993-0002